Hoth Therapeutics’ (HOTH) Buy Rating Reaffirmed at D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. D. Boral Capital’s target price would indicate a potential upside of 124.22% from the stock’s previous close.

HOTH has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a report on Monday, November 4th. Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a research report on Friday, October 11th.

Hoth Therapeutics Stock Performance

Hoth Therapeutics stock traded up $1.41 during midday trading on Tuesday, reaching $2.23. 335,950,001 shares of the company’s stock were exchanged, compared to its average volume of 82,185,336. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $3.80. The firm has a market cap of $15.40 million, a price-to-earnings ratio of -1.69 and a beta of 0.75. The stock’s 50-day simple moving average is $0.83 and its 200 day simple moving average is $0.84.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.01). Research analysts forecast that Hoth Therapeutics will post -1.18 earnings per share for the current year.

Institutional Investors Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent SEC filing. 7.08% of the stock is owned by hedge funds and other institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.